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Abstracts / Osteoarthritis and Cartilage 22 (2014) S57–S489S192costs were included, the average cost per quality adjusted life year
amounted to V 17,441, but the uncertainty around both CE-ratios
was substantial.
Conclusions: Over a period of 52 weeks, with a CE-ratio of – V 107,505
per QALY from the societal perspective and a CE-ratio of V 17,441 per
QALY from the healthcare perspective, our study revealed a consid-
erable probability that exercise therapy added to GP care is cost saving
or cost effective as compared to GP care alone.
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RESULTS FROM A SINGLE CENTER, DOUBLE-BLIND, RANDOMIZED,
PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY OF THE
EFFICACY AND SAFETY OF INTRA-ARTICULAR
ONABOTULINUMTOXINA FOR OSTEOARTHRITIS KNEE PAIN
K.C. Kalunian y, L. Arendt-Nielsen z, C.C. Turkel x, R. DeGryse x,
T.E. McAlindon k, A.J. Boon{, G.-L. Jiang x. yDept. of Med., Div. of
Rheumatology, Allergy, & Immunology, Univ. of California, San Diego, La
Jolla, CA, United States; zAalborg Univ., Sch. of Med., Ctr. for Sensory-
Motor Interaction, Aalborg E, Denmark; xAllergan, Inc., Irvine, CA,
United States; kDiv. of Rheumatology & Immunology, Tufts Med. Ctr.,
Boston, MA, United States; {Dept. of Physical Med. & Rehabilitation,
Dept. of Neurology, Mayo Clinic, Rochester, MN, United States
Purpose: The peripheral release of inﬂammatory mediators may sen-
sitize nociceptors, provoke central sensitization, and facilitate clinical
pain. Inhibition of the peripheral manifestations in knee osteoarthritis
(OA) by onabotulinumtoxinA (onabotA) may reduce the drive, central
consequences, and eventually clinical pain. Study objectives were to
determine the safety and efﬁcacy of a single intra-articular (IA) onabotA
injection in patients (pts) with painful knee OA.
Methods: Pts 40–75 y with knee OA (American College of Rheumatol-
ogy modiﬁed clinical classiﬁcation criteria; Kellgren-Lawrence grade I-
III) were enrolled in this 16-wk, single-center, double-blind, random-
ized, placebo-controlled, parallel-group phase 1b study. Pts were
stratiﬁed by baseline 14-day average daily worst pain score (ADWP;
4.0–9.0 [0–10 numeric rating scale]), and randomized (1:1) to ultra-
sound-guided injection of either onabotA (200 U) or placebo (saline).
Pts recorded worst daily pain for 2 wks before and 12 wks after injec-
tion (study visits: 1, 4, 8, 12 wks).
The planned primary efﬁcacy assessment was 14-day ADWP score
change from baseline, jointly analyzed for wks 4, 8, and 12 by repeated
measures analysis of covariance (RMANCOVA); secondary planned
efﬁcacy outcomes included Western Ontario McMaster (WOMAC) OA
Index (total, pain, and physical function scores) and pt global
impression of change (GIC). Other planned outcomes included the
PainDETECT questionnaire (PD-Q), assessed at baseline and each visit.
3 pain subtypes have been deﬁned by total PD-Q score: nociceptive
(PD-Q score 12), neuropathic (19), and uncertain (13 and 18).
Unplanned post-hoc analyses of primary and secondary outcomes by
baseline PD-Q pain subtype were performed. Safety data were col-
lected, including muscle strength around the knee (knee extension/
ﬂexion, ankle dorsiﬂexion/plantarﬂexion) for the study side and the
contralateral side.
The primary efﬁcacy assessment (intent-to-treat population) was ana-
lyzed using RMANCOVA for between-group comparisons, adjusted for
baseline ADWP score. Secondary efﬁcacy variables were analyzed with
a Wilcoxon rank-sum test; WOMAC analyses did not use a baseline
covariate. The safety population included all pts who received drug. All
randomized pts received the assigned drug.
Results: Of 170 screened pts, 121 were randomized to onabotA (n ¼ 61)
or placebo (n¼ 60). Mean agewas 62.3 y, all Caucasian, and comparable
male (n ¼ 59) and female (n ¼ 62) participation. No clinically relevant
between-group differences were observed at baseline.
The primary efﬁcacy analysis yielded no signiﬁcant difference between
onabotA and placebo for the change from baseline in ADWP score to the
3 prospectively deﬁned time points (P ¼ 0.70). Between-group differ-
ences were also not signiﬁcant for ADWP score change from baseline to
each individual time point (each of wks 2–12), WOMAC (total index,
pain, or physical function scores at wks 1, 4, 8, 12), or GIC (wks 1, 4, 8,
12). Post-hoc analyses by PD-Q pain subtype found numerically greater
improvement for all efﬁcacy outcomes among pts with nociceptive pain
(PD-Q12) who received onabotA (n ¼ 36) versus placebo (n ¼ 32)
across all time points (Figure); signiﬁcant differences were seen at wk 8
and/or 12 for all WOMAC outcomes and GIC.Adverse events (AEs) were reported for 24 pts (39.3%) receiving ona-
botA and 27 pts (45.0%) receiving placebo. Treatment-related AEs were
reported for both onabotA (arthralgia, n¼ 1 [1.6%]; burning sensation, n
¼ 1 [1.6%]) and placebo (n ¼ 1 [1.7%] each: arthralgia, arthropathy,
hypoaesthesia, joint stiffness, joint warmth, muscular weakness); all
were mild. Muscle strength evaluations found no decrease from base-
line in any knee or ankle extension/ﬂexion measure in either group at
any visit.
Conclusion: This exploratory study found no signiﬁcant between-
group differences in primary or secondary efﬁcacy endpoints;
improvement from baseline was observed for both treatment groups.
Post-hoc analyses found numerically greater improvement for all efﬁ-
cacy endpoints among the PD-Q nociceptive pain subtype that received
onabotA versus placebo, suggesting the PD-Q may be useful in identi-
fying onabotA-responsive pts with knee OA pain. Locally administered
onabotA (200 U IA) had an acceptable safety proﬁle and did not
decrease muscle strength around the knee. Further evaluation of ona-
botA efﬁcacy among pts with nociceptive knee OA pain is needed to
conﬁrm these post-hoc ﬁndings.
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Purpose: Pain is often the primary symptom of knee osteoarthritis (OA)
and results from a complex interaction between structural changes,
physical impairments and psychological factors. Much evidence sup-
ports the beneﬁts of strengthening exercise in this patient population.
There is also limited research supporting psychologist-delivered pain
coping skills training (PCST), a form of cognitive behavioural therapy, in
knee OA. Though typically provided separately, there are potential
symptom-, resource- and personnel-advantages of exercise and PCST
being delivered together by a single healthcare professional. Physi-
otherapists are a logical choice to be trained to deliver a PCST inter-
vention as they already have expertise in administering exercise and are
cognisant of the need for a biopsychosocial approach to management.
This study aimed to investigate whether an integrated 12-week exercise
and PCST treatment program delivered by physiotherapists is more
efﬁcacious than either program alone in treating pain and physical
function in individuals with knee OA.
Methods: The study utilized a 3-arm randomized controlled trial design
with measurements taken by a blinded assessor at baseline, 12, 32 and
52weeks following randomization. Twelveweeks was the primary time
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recruited from Melbourne and Brisbane, Australia and randomized to
one of three groups (i) Exercise; (ii) PCST; and (iii) Exercise plus PCST. All
groups visited a physiotherapist for ten sessions over 12 weeks. Par-
ticipants also performed home exercise and/or PCST home practice over
the trial duration. Primary outcomes were overall average pain in the
past week measured using the Visual Analogue Scale (VAS) and self-
reported physical function assessed by the Western Ontario and
McMaster Universities Osteoarthritis Index (WOMAC). Secondary out-
comes included global rating of change, WOMAC pain, VAS pain on
walking, muscle strength, functional performance, physical activity
levels, health-related quality-of-life and psychological factors. Stat-
istical analyses were performed on an intention-to-treat basis using all
randomized participants.
Results: Two hundred and twenty two participants were randomized
and 184 (82%) completed the 12-month trial. Baseline characteristics
were similar between the groups. For the primary outcomes all groups
showed signiﬁcantly improved VAS pain andWOMAC physical function
following treatment (Fig. 1) with no between-group differences for
pain. However, the integrated program resulted in signiﬁcantly greater
improvements in physical function compared to either intervention
alone at all time points (p < 0.02). Beneﬁts of the integrated program
over both programs alonewere also seen for VASwalking pain, WOMAC
pain, self-efﬁcacy and quality-of-life (p < 0.05). The integrated program
generally showed greater improvements in psychological parameters
compared to exercise alone and greater improvements in functional
performance compared to PCST alone.
Conclusions: Results of this novel study provide evidence of the ben-
eﬁts of an integrated exercise and PCST program for physical function,
pain and a range of physical and psychological outcomes in the short-
and longer-term for people with knee OA. This highlights the potential
for a newmodel of care involving physiotherapists. Advantages of using
physiotherapists to deliver PCST may include better integration with
exercise, increased availability of PCST treatment to those who may not
have access to a psychologist, reduced time and cost for patients, and
reduced overall costs to the health care system.Fig. 1. Mean (SD) change within groups, and adjusted mean [95% CI]
different in the change between groups for primary outcome meas-
ures. The latter were estimated with a mixed effects linear regression
model in which physiotherapists were treated as random effects and the
baseline scores of the outcome variables were entered as a covariate,
together with adjustment for the stratiﬁcation variable of site.332
SAFETY AND EFFICACY OF MM-II, AN INTRA-ARTICULAR INJECTION
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Bio-lubrication is a prerequisite for proper joint mobility and is crucial
for prevention of degradative changes of the joint. Phospholipids arecomponents of the synovial ﬂuid and are known to serve as natural
lubricants of cartilage surfaces. MM-II is a novel intra-articular bio-
lubricant made of liposomes suspended in aqueous solution.
Purpose: To test the safety and effectiveness of intra-articular injection
of MM-II in osteoarthritic patients compared with intra-articular hya-
luronic acid (HA) up to 3 months of follow-up in a preliminary double-
blind, randomized clinical study.
Method: Patients with symptomatic unilateral knee OA meeting ACR
criteria, with baseline pain on VAS of more than 40 mm and a stage 2–3
Kellgren Lawrence score on X-ray, were recruited. 40 patients were
randomized into two groups of 20, to receive a single intra-articular
injection of either MM-II or high molecular weight HA (Durolane).
Effectivenessmeasures includedmaximal global pain in the target knee,
recorded by a 100 mm VAS; WOMAC subscales; OMERACT OARSI res-
ponder criteria; PGA, PASS, PAE questions and consumption of para-
cetamol/acetaminophen.
Paracetamol/acetaminophen was the only authorized rescue medi-
cation. Tolerability was assessed by local manifestation deﬁned by an
increase in knee circumference of at least 3 cm in the knee circum-
ference, measured at 2 cm above the upper border of the patella or local
pain increase of more than 30 mm on a 100 mm VAS. Adverse events
were recorded through 90-days of follow-up.
The study was FIM Exploratory non-powered, with descriptive
statistics.
Results: All patients completed the study. In the HA group, the mean
patient age was 66.2 years, 9 males and 11females, and the average BMI
at baseline was 27.4. In the MM-II group, the mean patient age was 63.0
years, 11 males and 9 females, and the average BMI at baseline was 29.3.
The average pain at target knee at baseline was 53.1 mm in the HA
group and 55.9 mm in the MM-II group.
Results relating to WOMAC A pain are summarized in the Fig. 1, and
show a faster response with MM-II, with maximal effect observed on
day 14, which was maintained over time and was associated with a
statistically signiﬁcant difference from baseline pain from day 7. In
the HA group, the onset of pain relief was slower, with an
improvement statistically signiﬁcant change from baseline observed
only on day 90.
Daily acetaminophen intake was lower in the MM-II group, with a
reduction of more than 50 percent in the number of days and total dose
of rescue medication consumption seen following MM-II admin-
istration, compared with HA injection.
The percent of responders to treatment according to the OMERAC-
OARSI response criteria was 52.6, 66.7, 70 & 60 at the day 7, 14, 30 & 90
respectively compared to 30, 36.8, 25, 45 at the HA group.
Local adverse events (inﬂammatory ﬂare) were observed in one patient
at day 3 in the MM-II group and in 4 patient at day 1, 1 patient at day 3,
and 1 patient at day 7 in the HA group.
Patient’s Relative Change in WOMAC A in Target Knee over Time* Statistically signiﬁcant difference from baseline.
Conclusion: Intra-articular injections of MM-II were found to be safe
and effective. The pain-reduction action was more rapid and sustained
up to 3 months compared with HA. Larger randomized controlled trials
are needed to conﬁrm these encouraging results.
